Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.

Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory about inclusion of PZA in case of resistance. Moreo...

Full description

Bibliographic Details
Main Authors: Jean Claude Semuto Ngabonziza, Awa Ba Diallo, Elisa Tagliani, Bassirou Diarra, Abalo Essosimna Kadanga, Antieme Combo George Togo, Aliou Thiam, Willem Bram de Rijk, Riccardo Alagna, Sabine Houeto, Fatoumata Ba, Anoumou Yaotsè Dagnra, Emil Ivan, Dissou Affolabi, Valérie Schwoebel, Arnaud Trebucq, Bouke Catherine de Jong, Leen Rigouts, Géraldine Daneau, “Union short MDR-TB regimen study group”
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5663438?pdf=render

Internet

http://europepmc.org/articles/PMC5663438?pdf=render

Similar Items